External Reference Pricing Impact of the Integration of the Amnog Discount In The List Price

External Reference Pricing Impact of the Integration of the Amnog Discount In The List Price

2014 Value in health

Thivolet, M. | Cetinsoy, L. | Vataire, A.L. | Remuzat, C. | Brunet, J. | Kornfeld, A. | Toumi, M. | Volume: 17, Issue: 7, Pages: A423, Price, Value,

In Germany, the AMNOG law replaced free pricing by the early benefit assessment (EBA) since 2011. Manufacturers are free to set new drugs’ prices for up to one year after which the price is negotiated between manufacturers and insurers based on the EBA. The negotiated price, that is consistently lower than the one set by the manufacturers, is considered as the official list price since April 1st2014. The objective of this study is to evaluate the potential impact of this new law on the external reference pricing (ERP) in Europe.

https://www.doi.org/10.1016/j.jval.2014.08.1046; 10.1016/j.jval.2014.08.1046